A decade of discovery and development of new anti-malarial medicines has led to a
renewed focus on malaria elimination and eradication. Changes in the way new anti …

Plasmodium vivax is geographically the most widely distributed cause of malaria in people,
with up to 2· 5 billion people at risk and an estimated 80 million to 300 million clinical cases …

A highly protective malaria vaccine would greatly facilitate the prevention and elimination of
malaria and containment of drug-resistant parasites. A high level (more than 90%) of …

Consistent, high-level, vaccine-induced protection against human malaria has only been
achieved by inoculation of Plasmodium falciparum (Pf) sporozoites (SPZ) by mosquito bites …

Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmodium
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …

Our goal is to develop a vaccine that sustainably prevents Plasmodium falciparum (Pf)
malaria in≥ 80% of recipients. Pf sporozoites (PfSPZ) administered by mosquito bites are …

The human malaria parasite Plasmodium vivax is responsible for 25–40% of the∼ 515
million annual cases of malaria worldwide. Although seldom fatal, the parasite elicits severe …

Malaria liver stages represent an ideal therapeutic target with a bottleneck in parasite load
and reduced clinical symptoms; however, current in vitro pre-erythrocytic (PE) models for …

Plasmodium vivax malaria is characterized by periodic relapses of symptomatic blood stage
parasite infections likely initiated by activation of dormant liver stage parasites …

The unique relapsing nature of Plasmodium vivax infection is a major barrier to malaria
eradication. Upon infection, dormant liver-stage forms, hypnozoites, linger for weeks to …